Product Description
Human Glioblastoma (GBM) Circulating Tumor Cells - Frozen Vial
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor and is associated with a dismal prognosis. Although extracranial metastasis is exceedingly uncommon, recent studies have identified circulating tumor cells (CTCs) in the peripheral blood of patients with GBM. This discovery challenges the traditional notion that glioblastoma is a strictly localized disease and suggests that hematogenous dissemination may occur more frequently than previously recognized. Consequently, CTCs have emerged as a promising biomarker for liquid biopsy applications, offering potential utility for disease monitoring, prognostication, and therapeutic decision-making in neuro-oncology. Circulating tumor cells (CTC) originate from the primary tumor or metastatic deposits after intravasating through the tumor vasculature. Although most CTC die in the circulation, a proportion of them have the ability to spread, seed and proliferate in distant sites to form secondary metastasis, or reestablish into the organ of origin to form new tumors. CTC are rare events, estimated to account for one cell in a billion nucleated cells. There are sensitive CTC enrichment technologies that allow testing for the risk of cancer relapse based on shedding of CTC at time of treatment. This information may help guide future therapeutic decisions.
Positive Markers: Sox2,Oct4,NANOG,CD133,Telomerase,Vimentin (CSV),c-MET, Tubulin Beta-3 and Ki67.
Tumorigenicity ; < 1000 cells injection subcutaneously
Cells are supplied at 1.2 million cells per vial, with a guaranteed recovery of at least 1 million viable cells after thawing, provided that the cells are cultured using the appropriate Celprogen medium and pre-coated tissue culture ware.
Also Available as:
T25 plated cells shipped at room temperature. Cat# 36104-41CTC-T25
T75 plated cells shipped at room temperature. Cat# 36104-41CTC-T75
120 Population doublings or up to 12 passages.
One million viable cells upon thawing of frozen cells, frozen vial of cells shipped in dry-ice.
This product would require pre-coated flasks with Human GBM Circulating Tumor Cells Extra-cellular Matrix Cat# E36104-41CTC and Human GBM Circulating Tumor Cells Media Cat# M36104-41CTC
Cell cultures are derived from single donors, with more than 1,000 individual donor-derived cultures available. At the time of ordering, please specify the donor lot(s) and/or any desired glioblastoma (GBM) subcategory. If no specific donor lot or subcategory is requested, a Human GBM CTC culture will be selected at random from our inventory and supplied.
For non-academic use, please inquire for pricing.
Patient-Derived Xenograft (PDX) Platform
Access a collection of more than 1,000 fully characterized proprietary patient-derived xenograft (PDX) models representing all major cancer histotypes and capturing the breadth of tumor diversity.
Model Options
- Subcutaneous, orthotopic, and disseminated tumor models
- Extensive molecular and pharmacological characterization
- Detailed patient pretreatment histories to support optimal model selection
Integrated Translational Research Approach
Utilize the same PDX models and their corresponding 2D/3D cell line derivatives for in vitro screening and subsequent in vivo validation studies. This integrated strategy enables the identification of predictive biomarkers associated with tumor sensitivity to investigational compounds.
Featured Model
- PDX Model: PDX36104-41CTC
Customized Study Designs
Studies can be tailored to specific research objectives, including:
- Proof-of-concept evaluations
- Dose and schedule optimization
- Combination therapy assessments
- Biomarker discovery and validation
- Other project-specific translational research needs
